Combined delivery of an antiangiogenic protein (angiostatin) and an immunomodulatory gene (interleukin-12) in the treatment of murine cancer.
We investigated the feasibility of a novel therapeutic approach to treat neoplastic diseases in mice. This novel strategy consists in delivering a protein (angiostatin) with strong antiangiogenic properties, followed by administration of the interleukin 12 gene that is strongly immunomodulatory and has also some antiangiogenic effects. When angiostatin-mediated antiangiogenic therapy was used in combination with intratumor delivery of the IL-12 gene (a strategy much safer than IL-12 protein administration), this produced a synergistic therapeutic effect.
Wilczyńska
U
U
Department of Molecular Biology, Center of Oncology Maria Skłodowska-Curie Memorial Institute, Gliwice, Poland.
Kucharska
A
A
Szary
J
J
Szala
S
S
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D043168:Angiostatins; D000818:Animals; D015153:Blotting, Western; D002455:Cell Division; D004305:Dose-Response Relationship, Drug; D004591:Electrophoresis, Polyacrylamide Gel; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D018664:Interleukin-12 / Q000235:genetics*; D051379:Mice; D008810:Mice, Inbred C57BL; D009369:Neoplasms / Q000188:drug therapy*; D009389:Neovascularization, Pathologic; D010446:Peptide Fragments / Q000235:genetics*; D010957:Plasmids / Q000378:metabolism; D010958:Plasminogen / Q000235:genetics* / Q000378:metabolism; D013997:Time Factors; D014407:Tumor Cells, Cultured
D020533:Angiogenesis Inhibitors; D010446:Peptide Fragments; D016222:Fibroblast Growth Factor 2; D018664:Interleukin-12; D043168:Angiostatins; D010958:Plasminogen